Trial Profile
Phase I/II Trial of a Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral ß-glucan for High-Risk Neuroblastoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Jun 2023
Price :
$35
*
At a glance
- Drugs Neuroblastoma vaccine (Primary) ; OPT 821 (Primary) ; Beta Glucans
- Indications Neuroblastoma
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 01 Jun 2023 Planned End Date changed from 1 May 2023 to 1 May 2025.
- 01 Jun 2023 Planned primary completion date changed from 1 May 2023 to 1 May 2025.
- 13 Apr 2022 Results presented at the 113th Annual Meeting of the American Association for Cancer Research